EA201200597A1 - Моноклональные антитела к прогастрину и их применение - Google Patents

Моноклональные антитела к прогастрину и их применение

Info

Publication number
EA201200597A1
EA201200597A1 EA201200597A EA201200597A EA201200597A1 EA 201200597 A1 EA201200597 A1 EA 201200597A1 EA 201200597 A EA201200597 A EA 201200597A EA 201200597 A EA201200597 A EA 201200597A EA 201200597 A1 EA201200597 A1 EA 201200597A1
Authority
EA
Eurasian Patent Office
Prior art keywords
progastrin
methods
monoclonal antibodies
application
monoclonal
Prior art date
Application number
EA201200597A
Other languages
English (en)
Other versions
EA029271B1 (ru
Inventor
Жюли Паннекен
Лора Будье
Доминик Жубер
Фредерик Олланд
Original Assignee
Биориалите
Инститю Насьональ Де Ла-Санте Э Де Ла-Решерш Медикаль (Инсерм)
Сантр Насьональ Де Ла-Решерш Сайнтифик (Снрс)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200597(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Биориалите, Инститю Насьональ Де Ла-Санте Э Де Ла-Решерш Медикаль (Инсерм), Сантр Насьональ Де Ла-Решерш Сайнтифик (Снрс) filed Critical Биориалите
Publication of EA201200597A1 publication Critical patent/EA201200597A1/ru
Publication of EA029271B1 publication Critical patent/EA029271B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящая заявка является направленной на моноклональные антитела к прогастрину, их фрагменты, композиции, включающие моноклональные антитела к прогастрину, и способы получения и применения моноклональных антител к прогастрину и их композиций. Настоящая заявка является направленной на способы лечения колоректального рака с помощью моноклональных антител к прогастрину и композиций, включающих моноклональные антитела к прогастрину или их фрагменты. Настоящая заявка является также направленной на способы, включающие определение прогастрина, включая способы диагностики колоректального рака и способы мониторинга эффективности противораковой терапии у субъектов, страдающих от колоректального рака.
EA201200597A 2009-10-16 2010-10-15 Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения EA029271B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (2)

Publication Number Publication Date
EA201200597A1 true EA201200597A1 (ru) 2012-12-28
EA029271B1 EA029271B1 (ru) 2018-03-30

Family

ID=43086711

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791876A EA201791876A1 (ru) 2009-10-16 2010-10-15 Моноклональные антитела к прогастрину и их применение
EA201200597A EA029271B1 (ru) 2009-10-16 2010-10-15 Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791876A EA201791876A1 (ru) 2009-10-16 2010-10-15 Моноклональные антитела к прогастрину и их применение

Country Status (41)

Country Link
US (7) US9611320B2 (ru)
EP (2) EP3421493B1 (ru)
JP (3) JP5985987B2 (ru)
KR (2) KR101640520B1 (ru)
CN (2) CN104628857A (ru)
AP (1) AP2012006262A0 (ru)
AR (1) AR078659A1 (ru)
AU (1) AU2010306119A1 (ru)
BR (1) BR112012008818B1 (ru)
CA (1) CA2777691C (ru)
CL (1) CL2012000914A1 (ru)
CR (1) CR20120184A (ru)
CU (1) CU24196B1 (ru)
CY (1) CY1120913T1 (ru)
DK (1) DK2488551T3 (ru)
EA (2) EA201791876A1 (ru)
EC (1) ECSP12011796A (ru)
ES (2) ES2973217T3 (ru)
GE (1) GEP201706604B (ru)
GT (1) GT201200114A (ru)
HK (1) HK1178183A1 (ru)
HN (1) HN2012000708A (ru)
HR (1) HRP20181645T1 (ru)
IL (2) IL219019B (ru)
IN (1) IN2012DN03348A (ru)
LT (1) LT2488551T (ru)
MA (1) MA33747B1 (ru)
MX (1) MX351635B (ru)
NI (1) NI201200054A (ru)
NZ (2) NZ599971A (ru)
PE (1) PE20121649A1 (ru)
PL (2) PL3421493T3 (ru)
PT (1) PT2488551T (ru)
RS (1) RS57966B1 (ru)
SG (1) SG10201704933PA (ru)
SI (1) SI2488551T1 (ru)
TN (1) TN2012000159A1 (ru)
TW (1) TWI537002B (ru)
UA (1) UA106771C2 (ru)
WO (1) WO2011045080A2 (ru)
ZA (1) ZA201202642B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
PT2488551T (pt) * 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
SG184092A1 (en) * 2010-03-24 2012-10-30 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
EA028515B1 (ru) * 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
US8785603B2 (en) * 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
US9803017B2 (en) 2013-07-05 2017-10-31 University Of Washington Through Its Center For Commercialization Soluble MIC neutralizing monoclonal antibody for treating cancer
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
AU2015247358B2 (en) * 2014-04-18 2020-02-27 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
AU2016324021A1 (en) * 2015-09-15 2018-04-12 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
BR112018013268A2 (pt) * 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer gástrico
KR102507685B1 (ko) * 2015-12-31 2023-03-08 프로가스트린 에 캔서스 에스.에이 알.엘. 난소암의 검출 및 치료를 위한 조성물 및 방법
WO2017114973A1 (en) * 2015-12-31 2017-07-06 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence
ES2926532T3 (es) * 2017-03-30 2022-10-26 Progastrine Et Cancers S A R L Composiciones y métodos para tratar el cáncer de pulmón
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
CA3084687C (en) * 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU2018381046A1 (en) 2017-12-08 2020-07-16 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
AU2019228339A1 (en) * 2018-02-27 2020-09-10 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN117567611B (zh) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1794586B1 (en) * 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
JP5651331B2 (ja) * 2006-05-22 2015-01-14 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 結腸直腸癌の治療におけるプロガストリン阻害剤
WO2008076454A1 (en) * 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
PT2488551T (pt) * 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações

Also Published As

Publication number Publication date
US20170306011A1 (en) 2017-10-26
ES2690943T3 (es) 2018-11-23
IL219019B (en) 2019-05-30
BR112012008818A2 (pt) 2018-05-22
ES2973217T3 (es) 2024-06-19
KR101640520B1 (ko) 2016-07-19
TW201119675A (en) 2011-06-16
ZA201202642B (en) 2013-06-26
HRP20181645T1 (hr) 2018-12-14
US20200002413A1 (en) 2020-01-02
IN2012DN03348A (ru) 2015-10-23
BR112012008818B1 (pt) 2021-10-19
MA33747B1 (fr) 2012-11-01
JP5985987B2 (ja) 2016-09-06
EP2488551A2 (en) 2012-08-22
US10377821B2 (en) 2019-08-13
NI201200054A (es) 2012-08-20
MX351635B (es) 2017-10-23
SG10201704933PA (en) 2017-07-28
US20110117086A1 (en) 2011-05-19
US9611320B2 (en) 2017-04-04
SI2488551T1 (sl) 2019-01-31
CN102791735A (zh) 2012-11-21
IL254004A0 (en) 2017-10-31
US10385125B2 (en) 2019-08-20
KR20120091221A (ko) 2012-08-17
CA2777691A1 (en) 2011-04-21
CA2777691C (en) 2018-02-27
NZ701709A (en) 2016-06-24
US10385126B2 (en) 2019-08-20
JP2013507138A (ja) 2013-03-04
EP2488551B1 (en) 2018-07-25
CU24196B1 (es) 2016-09-30
AP2012006262A0 (en) 2012-06-30
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
EP3421493C0 (en) 2024-01-17
WO2011045080A3 (en) 2011-07-07
EP3421493B1 (en) 2024-01-17
HN2012000708A (es) 2015-06-22
PL2488551T3 (pl) 2019-01-31
EP3421493A1 (en) 2019-01-02
US11299542B2 (en) 2022-04-12
KR20150082672A (ko) 2015-07-15
AU2010306119A1 (en) 2012-05-03
LT2488551T (lt) 2018-10-25
WO2011045080A2 (en) 2011-04-21
CL2012000914A1 (es) 2012-09-14
TN2012000159A1 (en) 2013-12-12
GEP201706604B (en) 2017-01-25
HK1178183A1 (zh) 2013-09-06
UA106771C2 (ru) 2014-10-10
US20180022802A1 (en) 2018-01-25
CN104628857A (zh) 2015-05-20
IL219019A0 (en) 2012-06-28
IL254004B2 (en) 2023-06-01
NZ599971A (en) 2014-12-24
CU20120060A7 (es) 2013-04-19
ECSP12011796A (es) 2012-06-29
JP2017212992A (ja) 2017-12-07
CY1120913T1 (el) 2019-12-11
US20170306012A1 (en) 2017-10-26
CR20120184A (es) 2012-08-20
PE20121649A1 (es) 2012-12-08
MX2012004400A (es) 2012-06-27
US20170174761A1 (en) 2017-06-22
EA029271B1 (ru) 2018-03-30
JP6272793B2 (ja) 2018-01-31
PL3421493T3 (pl) 2024-04-29
GT201200114A (es) 2014-08-11
RS57966B1 (sr) 2019-01-31
EA201791876A1 (ru) 2018-01-31
TWI537002B (zh) 2016-06-11
US20220195035A1 (en) 2022-06-23
DK2488551T3 (en) 2018-10-08
JP2015145380A (ja) 2015-08-13
PT2488551T (pt) 2018-10-31
US10385124B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
EA201200597A1 (ru) Моноклональные антитела к прогастрину и их применение
EA201170716A1 (ru) Антитела к с-мет
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
PH12014502419A1 (en) Specific binding proteins and uses thereof
EA201171374A1 (ru) Антитела против cd100 и способы их применения
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
UA103916C2 (en) Dkk-1 antibody
EA201391423A1 (ru) Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
NZ607472A (en) Treatment for neoplastic diseases
EA201001603A1 (ru) Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование
WO2013149219A3 (en) Fully human antibodies that bind to vegfr2
UA104739C2 (en) c-MET ANTIBODIES
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
TH133902A (th) มอนอโคลนัลแอนติบอดีสำหรับโพรแกสตรินและการใช้ประโยชน์ของมอนอโคลนัลแอนติบอดี
TH133902B (th) มอนอโคลนัลแอนติบอดีสำหรับโพรแกสตรินและการใช้ประโชน์ของมอนอโคลนัล แอนติบอดี

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM